Berberine vs Canagliflozin
'Nature's Ozempic' against a real prescription SGLT2 drug with an actual, if mouse-only, longevity signal the OTC alternative doesn't have.
Short answer
Only canagliflozin is FDA-approved; berberine is not. Canagliflozin is the one to look at if FDA approval matters to you, though that approval does not cover every use it is marketed for, while berberine is marketed for blood sugar and lipids. On the evidence, berberine has human clinical data and canagliflozin has approval-level evidence.
Berberine
Real (low-certainty) human evidence for glucose and lipids; the 'nature's Ozempic' weight-loss claim is not supported.
Full Berberine evidence reviewCanagliflozin
Invokana
FDA-approved SGLT2 inhibitor with real cardiovascular and renal outcome trials (CANVAS, CREDENCE) — but the longevity claim rests entirely on a 14% median-lifespan extension in male-only NIA ITP mice; no human longevity trial exists, and the drug carries real risks (amputation, Fournier's gangrene, euglycemic DKA) that apply the same whether it's prescribed for diabetes or taken off-label for aging.
Full Canagliflozin evidence reviewBerberine vs Canagliflozin: head to head
- FDA status / approved use
Berberine
Sold as a supplementCanagliflozin
FDA-approved (Invokana) for type 2 diabetes; longevity use is off-label and untested in humans- Marketed for
Berberine
Blood sugar, lipids, 'nature's Ozempic'Canagliflozin
Type 2 diabetes (approved); explored off-label for longevity on mouse ITP data- Outcome areas
Berberine
Blood sugar / insulin sensitivity; CardiovascularCanagliflozin
Blood sugar / insulin sensitivity; Cardiovascular; Longevity / lifespan- Evidence grade
Berberine
Clinical dataCanagliflozin
FDA-approved- How it works
Berberine
Activates AMPK, a cellular energy switch; not a GLP-1 drugCanagliflozin
Blocks the kidney's SGLT2 transporter so glucose leaves the body in urine- Route and dosing
Berberine
Supplement; 500 mg three times daily in the key head-to-head trialCanagliflozin
Oral tablet, prescription only- Headline human result
Berberine
HbA1c fell from 9.5% to 7.5% over three months in a head-to-head pilot, similar to metforminCanagliflozin
Major cardiovascular events cut, hazard ratio 0.86 vs placebo, in the CANVAS Program of about 10,000 people with type 2 diabetes- Strongest evidence
Berberine
Meta-analysis, J Ethnopharmacol 2015Berberine evidence reviewPubMed 25498346Canagliflozin
Miller 2020 NIA ITP, JCI InsightCanagliflozin evidence reviewPubMed 32990681- Key safety signal
Berberine
Transient GI effects in about a third of patients; inhibits CYP3A4, so interacts with many medicationsCanagliflozin
Ketoacidosis, genital infections, Fournier's gangrene, volume depletion and raised lower-limb amputation risk- How it is obtained
Berberine
Over the counter as a dietary supplementCanagliflozin
Prescription drug
| Berberine | Canagliflozin | |
|---|---|---|
| FDA status / approved use | Sold as a supplement | FDA-approved (Invokana) for type 2 diabetes; longevity use is off-label and untested in humans |
| Marketed for | Blood sugar, lipids, 'nature's Ozempic' | Type 2 diabetes (approved); explored off-label for longevity on mouse ITP data |
| Outcome areas | Blood sugar / insulin sensitivity; Cardiovascular | Blood sugar / insulin sensitivity; Cardiovascular; Longevity / lifespan |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Activates AMPK, a cellular energy switch; not a GLP-1 drug | Blocks the kidney's SGLT2 transporter so glucose leaves the body in urine |
| Route and dosing | Supplement; 500 mg three times daily in the key head-to-head trial | Oral tablet, prescription only |
| Headline human result | HbA1c fell from 9.5% to 7.5% over three months in a head-to-head pilot, similar to metformin | Major cardiovascular events cut, hazard ratio 0.86 vs placebo, in the CANVAS Program of about 10,000 people with type 2 diabetes |
| Strongest evidence | Meta-analysis, J Ethnopharmacol 2015Berberine evidence reviewPubMed 25498346 | Miller 2020 NIA ITP, JCI InsightCanagliflozin evidence reviewPubMed 32990681 |
| Key safety signal | Transient GI effects in about a third of patients; inhibits CYP3A4, so interacts with many medications | Ketoacidosis, genital infections, Fournier's gangrene, volume depletion and raised lower-limb amputation risk |
| How it is obtained | Over the counter as a dietary supplement | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Berberine has real, low-certainty human evidence for glucose and lipids, but the 'nature's Ozempic' weight-loss framing is not supported by its trial record, and it has no mouse or human longevity data of its own. Canagliflozin is a stronger glucose-lowering drug with real cardiovascular/renal outcome trials (CANVAS, CREDENCE) and a genuine, repeatable NIA ITP mouse-lifespan signal — but it requires a prescription and carries real risks berberine doesn't, including amputation and Fournier's gangrene.
Berberine fits if
You want an OTC option for glucose/lipid support without a prescription, and you're not chasing a longevity signal specifically.
Canagliflozin fits if
Glycemic control is a genuine medical need best met with a prescription drug, or the ITP longevity signal specifically is what you're following, understood as mouse-only evidence.
Berberine vs Canagliflozin: common questions
- Is canagliflozin FDA-approved but berberine not?
- Yes. Canagliflozin is FDA-approved (Invokana) for type 2 diabetes; longevity use is off-label and untested in humans. Berberine is sold as a supplement.
- Which has stronger human evidence, berberine or canagliflozin?
- Canagliflozin. It has approval-level evidence (key source: Miller 2020 NIA ITP, JCI Insight), while berberine has human clinical data (key source: Meta-analysis, J Ethnopharmacol 2015).
- What are the main safety concerns with berberine and canagliflozin?
- For berberine, watch for transient GI effects in about a third of patients; inhibits CYP3A4, so interacts with many medications. For canagliflozin, watch for ketoacidosis, genital infections, Fournier's gangrene, volume depletion and raised lower-limb amputation risk.
Key studies behind each
Berberine
- Lee YS, Kim WS, Kim KH, et al. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. PubMed 16873688
- Lan J, Zhao Y, Dong F, et al. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. PubMed 25498346
- Yin J, Xing H, Ye J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. PubMed 18442638
- Kong W, Wei J, Abidi P, et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. PubMed 15531889
Canagliflozin
- Miller RA, Harrison DE, Allison DB, et al. (2020). Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. PubMed 32990681
- Jayarathne HSM, Debarba LK, Jaboro JJ, Ginsburg BC, Miller RA, Sadagurski M. (2022). Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice. Aging Cell. PubMed 35707855
- Neal B, Perkovic V, Mahaffey KW, et al. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Program). N Engl J Med. PubMed 28605608
- Perkovic V, Jardine MJ, Neal B, et al. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). N Engl J Med. PubMed 30990260
The full evidence reviews
- Berberine: real evidence for blood sugar, not for weight loss
A plant alkaloid that activates AMPK and lowers glucose and LDL in human trials — with effects on blood sugar comparable to oral diabetes drugs. But it's not a GLP-1, and 'nature's Ozempic' is a myth.
Updated August 2026
- Canagliflozin and longevity: a diabetes drug with a male-only mouse-lifespan signal
An approved SGLT2 inhibitor that extended median lifespan 14% in male NIA mice, with no benefit in females — a prescriber decision, not a supplement purchase.
Updated August 2026